Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7 Carcinoma, Hepatocellular 4 Rectal Neoplasms 2 Stomach Neoplasms 1 Peripheral Nervous System Diseases 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Colonic Neoplasms 1 Biliary Tract Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 3 lenvatinib 2 sintilimab 1 pembrolizumab 1 halofantrine 1 glucose-regulated proteins 1 camrelizumab 1 Tranexamic Acid 1 Thalidomide 1 Sunitinib 1 Standard of Care 1 Saline Solution 1 Oxaliplatin 1 Nadroparin 1 Lidocaine 1 Injections 1 Immune Checkpoint Inhibitors 1 Heparin, Low-Molecular-Weight 1 Gemcitabine 1 Folfox protocol 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Liver Neoplasms × Folfox protocol × Clear all

NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡